protein tyrosine phosphatase non-receptor type 7Genealiases: BPTP-4 · HEPTP · LC-PTP · LPTP · PTPNI
Q-omics provides the consensus-scored PTPN7 profile across patient tissues and cancer cell-line models. PTPN7 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PTPN7 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PTPN7 protein abundance shows 24,788 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where PTPN7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTPN7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTPN7 survival associations across molecular data types. PTPN7 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTPN7 RNA expression–survival associations across cancer types. High PTPN7 expression shows unfavorable associations in UVM and LGG, but favorable associations in HNSC, SKCM, UCEC and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PTPN7 RNA expression.
This table summarizes PTPN7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PTPN7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTPN7 shows higher tumor expression in KIRC, HNSC, STAD, LUAD, BRCA and LIHC. The KIRC box plot shows higher PTPN7 RNA expression in tumor versus normal tissue (log2 FC = +1.681, t-test p < 0.001).
This table shows molecular features associated with PTPN7 in patient tissues and cancer cell lines. In patient samples, PTPN7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PTPN7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_NSCLC_LUAD.
